KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Gross Margin (2023 - 2025)

Biocryst Pharmaceuticals' Gross Margin history spans 8 years, with the latest figure at 1244.92% for Q4 2025.

  • For Q4 2025, Gross Margin fell 134028.0% year-over-year to 1244.92%; the TTM value through Dec 2025 reached 95.93%, down 135.0%, while the annual FY2025 figure was 97.82%, 54.0% up from the prior year.
  • Gross Margin reached 1244.92% in Q4 2025 per BCRX's latest filing, down from 98.63% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.78% in Q4 2023 to a low of 1244.92% in Q4 2025.
  • Average Gross Margin over 3 years is 51.41%, with a median of 98.29% recorded in 2025.
  • The largest YoY upside for Gross Margin was 137bps in 2025 against a maximum downside of -134028bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 98.78% in 2023, then fell by -3bps to 95.37% in 2024, then plummeted by -1405bps to 1244.92% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Gross Margin are 1244.92% (Q4 2025), 98.63% (Q3 2025), and 98.29% (Q2 2025).